Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study

Abstract

There is a paucity of data on incidence, prevalence and mortality associated with non-cystic fibrosis bronchiectasis.

Quality standards for the management of bronchiectasis in Italy: a national audit

“…49% had been hospitalised at least once in the previous year for lower respiratory tract infections (LRTI). The median (IQR) number of antibiotic courses for LRTI in the previous year was 2 (2)(3), with 40% of the study population receiving three or more antibiotic courses in the previous year. Specifically, 36% of them received at least one course of intravenous antibiotics because of an exacerbation during the previous year.…”

“…Although historically considered a neglected disease, bronchiectasis has become a disease of renewed interest over recent decades in light of an increase in prevalence and a substantial burden on healthcare systems [1][2][3]. In 2010, the British Thoracic Society (BTS) published guidelines on the management of bronchiectasis in adults, along with specific quality standards [4,5].…”

Suspecting non-cystic fibrosis bronchiectasis: What the busy primary care clinician needs to know

“…Although NCFB was once a very uncommon diagnosis, in the last two decades its prevalence has been increasing, making it more likely that primary care clinicians will encounter these patients in their practice. The precise prevalence of NCFB is difficult to determine because estimates vary among populations, but studies report a prevalence ranging from 486 to 1106 per 100 000 persons with an incidence that appears to be rising, particularly in women and older individuals 4, 5, 6. Although not as common as asthma, which affects approximately 10% of the world population, NCFB has become far more common than other respiratory conditions such as idiopathic pulmonary fibrosis, which affects only 18.2 per 100 000 persons 7, 8.…”

Management of chronic airway diseases: What can we learn from real-life data?

“…AATD is the primary diagnosis in approximately 1% of COPD cases and is typically associated with a more severe course; yet, the majority of cases go undetected because screening tests in at-risk populations are underutilised (8). Bronchiectasis is becoming increasingly prevalent, particularly in older age groups (ࣙ50 years), and is associated with substantially greater mortality compared with that in the general population (6). Overlap between these three conditions tends to worsen prognosis and has major implications for investigative and treatment strategies (9).…”

“…A diagnosis of bronchiectasis is made more likely by the fact that most patients are female and that average age at presentation is around 60 years (5). Cough, sputum and airflow obstruction are common findings and a large proportion of patients are initially diagnosed with COPD before the correct diagnosis is made by CT scan (6).…”